Frontline Treatment Options for Hodgkin's Lymphoma

Video

Frontline Treatment Options for Hodgkin's Lymphoma

A 32-Year-Old Man with Stage IV Hodgkin's Lymphoma

  • History & Physical:
    • A 32-year-old man presented to his PCP in January 2017 complaining of abdominal pain, pruritus, fevers of over 101⁰ F, and weight loss
  • Imaging
    • PET scan showed avid mediastinal mass
  • Labs
    • HgB 12.2 g/dL
    • WBC 7,500 mm2
    • ALC 3,200 mm2
    • Albumin 3.9 mg/dL
    • ANC 4,200/mm3
    • Liver and renal function tests WNL
  • Biopsy confirmed mixed cellularity classical Hodgkin’s lymphoma (HL)
  • Normal lung and cardiac function
  • Final Staging: Stage IVB, cHL, IPS score 2
  • ECOG PS 2
  • He received 2 cycles of ABVD. PET/CT restaging showed Deauville (1-). He received 4 additional cycles of AVD
  • He achieved a CR
  • 2 years after completion of therapy, the patient complained of a persistent cough and fatigue
  • PET/CT showed bilateral mediastinal masses
  • Biopsy confirmed cHL
Related Videos
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Joshua K. Sabari, MD, an expert on lung cancer
Related Content
FDA Approves Pirtobrutinib in CLL and SLL

FDA Approves Pirtobrutinib in CLL and SLL

December 4th 2023
Article

The FDA has granted accelerated approval to pirtobrutinib for the treatment of patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Read More

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

Examining the Non-Hodgkin Lymphoma Treatment Paradigm

July 15th 2022
Podcast

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

Listen

FDA Grants Epcoritamab Breakthrough Drug Designation for FL

FDA Grants Epcoritamab Breakthrough Drug Designation for FL

November 27th 2023
Article

The FDA breakthrough drug designation for epcoritamab in follicular lymphoma was supported by findings from the phase 1/2 EPCORE NHL-1 study.

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

SIRPant-M Receives FDA Orphan Drug Designation for T-Cell Lymphoma

SIRPant-M Receives FDA Orphan Drug Designation for T-Cell Lymphoma

November 15th 2023
Article

SIRPant-M has been granted orphan drug designation by the FDA for patients with T-cell lymphoma.

Read More

Pembrolizumab After ASCT is Feasible in Peripheral T-Cell Lymphoma

Pembrolizumab After ASCT is Feasible in Peripheral T-Cell Lymphoma

November 7th 2023
Article

In an interview, Mwanasha Merrill discussed the implication of findings from a phase 2 trial of pembrolizumab after autologous stem cell transplantation for the treatment of patients with peripheral T-cell lymphoma.

Read More